Effect of a broad-specificity chemokine-binding protein on brain leukocyte infiltration and infarct development

Stroke

Volumn 46, Issue 2, 2015, Pages 537-544

  Lee, Seyoung ^a   Chu, Hannah X ^a   Kim, Hyun Ah ^a   Real, Nicola C ^b   Sharif, Saeed ^b   Fleming, Stephen B ^b   Mercer, Andrew A ^b   Wise, Lyn M ^b   Drummond, Grant R ^a   Sobey, Christopher G ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

chemokine binding protein; chemokines; infarct; ischemia reperfusion; leukocytes; middle cerebral artery occlusion

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; BINDING PROTEIN; BOVINE SERUM ALBUMIN; BRAIN PROTEIN; CHEMOKINE; CHEMOKINE BINDING PROTEIN; CXCL2 CHEMOKINE; GAMMA CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BOVINE PAPULAR STOMATITIS VIRUS; BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN INFARCTION SIZE; CELL INFILTRATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; LEUKOCYTE; MALE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; REPERFUSION; REPERFUSION INJURY; SURFACE PLASMON RESONANCE; ANIMAL; BOVINE; BRAIN; C57BL MOUSE; CEREBRAL INFARCTION; DRUG EFFECTS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY;

ANIMALS; BRAIN; CATTLE; CEREBRAL INFARCTION; CHEMOKINE CXCL2; CHEMOTAXIS, LEUKOCYTE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; PROTEIN BINDING;

EID: 84922236716     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007298     Document Type: Article

References (33)

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292. doi: 10.1161/01.cir.0000441139.02102.80.
3. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391-397.
4. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808. doi: 10.1038/nm.2399.
5. Nibbs RJ, Graham GJ. Immune regulation by atypical chemokine receptors. Nat Rev Immunol. 2013;13:815-829.
6. Williams JL, Holman DW, Klein RS. Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers. Front Cell Neurosci. 2014;8:154. doi: 10.3389/fncel.2014.00154.
7. Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab. 2010;30:459-473. doi: 10.1038/jcbfm.2009.240.
8. Reaux-Le Goazigo A, Van Steenwinckel J, Rostene W, Melik Parsadaniantz S. Current status of chemokines in the adult CNS. Prog. Neurobiol. 2013;104:67-92.
9. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation-therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013;65:47-89. doi: 10.1124/pr.111.005074.
10. Mirabelli-Badenier M, Braunersreuther V, Viviani GL, Dallegri F, Quercioli A, Veneselli E, et al. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost. 2011;105:409-420. doi: 10.1160/TH10-10-0662.
11. Brait VH, Rivera J, Broughton BR, Lee S, Drummond GR, Sobey CG. Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome. Brain Res. 2011;1372:169-179. doi: 10.1016/j.brainres.2010.11.087.
12. Webb LM, Alcami A. Virally encoded chemokine binding proteins. Mini Rev Med Chem. 2005;5:833-848.
13. Seet BT, McCaughan CA, Handel TM, Mercer A, Brunetti C, McFadden G, et al. Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors. Proc Natl Acad Sci U S A. 2003;100:15137-15142. doi: 10.1073/pnas.2336648100.
14. Lateef Z, Baird MA, Wise LM, Mercer AA, Fleming SB. Orf virusencoded chemokine-binding protein is a potent inhibitor of inflammatory monocyte recruitment in a mouse skin model. J Gen Virol. 2009;90(pt 6):1477-1482. doi: 10.1099/vir.0.009589-0.
15. Lateef Z, Baird MA, Wise LM, Young S, Mercer AA, Fleming SB. The chemokine-binding protein encoded by the poxvirus orf virus inhibits recruitment of dendritic cells to sites of skin inflammation and migration to peripheral lymph nodes. Cell Microbiol. 2010;12:665-676. doi: 10.1111/j.1462-5822.2009.01425.x.
16. Delhon G, Tulman ER, Afonso CL, Lu Z, de la Concha-Bermejillo A, Lehmkuhl HD, et al. Genomes of the parapoxviruses ORF virus and bovine papular stomatitis virus. J Virol. 2004;78:168-177.
17. Hautaniemi M, Ueda N, Tuimala J, Mercer AA, Lahdenperä J, McInnes CJ. The genome of pseudocowpoxvirus: comparison of a reindeer isolate and a reference strain. J Gen Virol. 2010;91(pt 6):1560-1576. doi: 10.1099/vir.0.018374-0.
18. Corbett M, Real NC, Fleming SB, Mercer AA, Wise LM. The orf virus chemokine binding protein is a novel broad-spectrum chemokine inhibitor. NZ Med J. 2009;122:113-114.
19. Gassmann U, Wyler R, Wittek R. Analysis of parapoxvirus genomes. Arch Virol. 1985;83:17-31.
20. Inder MK, Ueda N, Mercer AA, Fleming SB, Wise LM. Bovine papular stomatitis virus encodes a functionally distinct VEGF that binds both VEGFR-1 and VEGFR-2. J Gen Virol. 2007;88(pt 3):781-791. doi: 10.1099/vir.0.82582-0.
21. Deane D, Ueda N, Wise LM, Wood AR, Percival A, Jepson C, et al. Conservation and variation of the parapoxvirus GM-CSF-inhibitory factor (GIF) proteins. J Gen Virol. 2009;90(pt 4):970-977. doi: 10.1099/vir.0.006692-0.
22. Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond GR, Sobey CG. Reduction of cerebral infarct volume by apocynin requires pretreatment and is absent in Nox2-deficient mice. Br J Pharmacol. 2009;156:680-688. doi: 10.1111/j.1476-5381.2008.00073.x.
23. Lee S, Brait VH, Arumugam TV, Evans MA, Kim HA, Widdop RE, et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med. 2012;4:16. doi: 10.1186/2040-7378-4-16.
24. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17: 472-476.
25. Chu HX, Kim HA, Lee S, Moore JP, Chan CT, Vinh A, et al. Immune cell infiltration in malignant middle cerebral artery infarction: comparison with transient cerebral ischemia. J Cereb Blood Flow Metab. 2014;34:450-459. doi: 10.1038/jcbfm.2013.217.
26. Jaerve A, Müller HW. Chemokines in CNS injury and repair. Cell Tissue Res. 2012;349:229-248. doi: 10.1007/s00441-012-1427-3.
27. Patel AR, Ritzel R, McCullough LD, Liu F. Microglia and ischemic stroke: a double-edged sword. Int J Physiol Pathophysiol Pharmacol. 2013;5:73-90.
28. Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, et al. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation. 2013;10:86. doi: 10.1186/1742-2094-10-86.
29. Thacker MA, Clark AK, Bishop T, Grist J, Yip PK, Moon LD, et al. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009;13:263-272. doi: 10.1016/j.ejpain.2008.04.017.
30. Chen Y, Hallenbeck JM, Ruetzler C, Bol D, Thomas K, Berman NE, et al. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab. 2003;23:748-755. doi: 10.1097/01.WCB.0000071885.63724.20.
31. Strecker JK, Minnerup J, Schütte-Nütgen K, Gess B, Schäbitz WR, Schilling M. Monocyte chemoattractant protein-1-deficiency results in altered blood-brain barrier breakdown after experimental stroke. Stroke. 2013;44:2536-2544. doi: 10.1161/STROKEAHA.111.000528.
32. Brait VH, Arumugam TV, Drummond GR, Sobey CG. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab. 2012;32:598-611. doi: 10.1038/jcbfm.2012.6.
33. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159-175. doi: 10.1038/nri3399.